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Approximately 6.5 million Americans suffer from chronic non-healing wounds each 
year with the average cost of treatment estimated to be $3,927 per incidence[1]. This 
pathological wound healing is typically indicative of a chronically inflamed environment 
that is unable to promote successful angiogenesis and collagen production to heal the 
wound. An approach for improving angiogenesis in chronic non-healing wounds is 
through the use of mesenchymal stromal/stem cells (MSCs). It has been shown that 
MSCs enhance wound healing due to their ability to both modulate the immune response 
to prevent a chronically inflamed environment and their ability to promote angiogenesis. 
MSCs promote angiogenesis through secretion of growth factors such as VEGF that 
recruit endothelial progenitor cells that are critical for rebuilding the damaged vasculature 
[2], [3]. In hypoxic environments, the pro-angiogenic effects of MSCs are enhanced 
through stimulation of the HIF-1α pathway[4]. Small molecules termed prolyl 
hydroxylase inhibitors (PHDi) stimulate the HIF-1α pathway through inhibition of prolyl 
hydroxylase (PHD) the protein involved in HIF-1α degradation. PHDi have been shown 
to chemically induce a hypoxic response from MSCs[5] and may allow for greater 
control over the pro-angiogenic secretory response of transplanted cells by increasing the 
duration and dosage of exposure.  In addition to hypoxia the culture format can affect the 
angiogenic properties of MSCs. The culture of MSCs as three dimensional spheroids has 
been shown to promote secretion of angiogenic growth factors such as VEGF[6] as well 
as immunomodulatory factors[7]. The objective of this project was to investigate methods 
to enhance the pro-angiogenic factor secretion of MSCs, which would lead to improved 
strategies for treatment of chronic non-healing wounds. The overall hypothesis was that 
sustained PHDi treatment and three-dimensional culture would lead to an enhancement of 
pro-angiogenic factor secretion from MSCs.  
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Treatment of MSCs with PHDi has been shown to enhance cell survival[8], improve 
bone regeneration[9], and increase new vessel formation in vivo[9].  
Dimethyloxalyglycine (DMOG), and ethyl 3,4-dihydroxybenzoate(3,4-DHB) are two of 
several PHDi that have been investigated in MSCs and shown to activate the HIF-1α 
pathway. However, a potentially more promising candidate is N-[[1,2-dihydro-4-
hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]carbonyl]-glycine (IOX2)[10] due to its 
higher specificity for PHD than other PHDi. However, the potency of IOX2 in 
modulating the angiogenic secretion of MSCs has not been studied. To compare the 
potency of DMOG, IOX2, and 3,4 DHB on the pro-angiogenic factor secretion of MSCs, 
a systematic screen was performed of each PHDi at a range of concentrations previously 
reported to be effective in other cell types. Vascular endothelial growth factor (VEGF) 
was used as the primary indicator of a pro-angiogenic response due to the well 
established link between VEGF and angiogenesis. Cell number was used as an indicator 
of cell growth. The results demonstrated that DMOG and IOX2 were the most potent 
inhibitors and optimized dosages were identified that produced the highest VEGF 
secretion without adversely affecting cell growth.  
The culture of MSCs as three-dimensional spheroids rather than monolayer culture 
has been shown to increase paracrine factor secretion[7][11], [12]. Thus, the effects of 
PHDi treatment on MSC spheroids was hypothesized to further enhance VEGF secretion 
compared to monolayer cultures. MSC spheroids were formed by forced aggregation and 
cultured in rotary culture for 3 days while being treated with either DMOG or IOX2. As 
expected, spheroid culture alone increased VEGF secretion by 6 fold. Addition of PHDi 
increased secretion of VEGF by 2-fold in both monolayer and spheroid cultures. This 
demonstrates that the combined strategy of PHDi treatment and spheroid culture is a 
viable option to enhance the pro-angiogenic factor secretion of MSCs. 
PHDi stabilization of HIF-1α is a transient effect, thus sustained exposure to PHDi 
could promote sustained secretion of pro-angiogenic factors. Sustained delivery of PHDi 
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could be achieved within spheroids via biomaterial based microparticle 
incorporation[13]. The delivery of PHDi from microparticles within spheroids allows for 
controlled PHDi presentation from within the spheroids, rather than requiring treatment 
with soluble PHDi in the culture media. This is particularly important for clinical 
translation, in which the spheroids would be treated beforehand and transplanted into the 
body. Thus the encapsulation of DMOG and IOX2 into PLGA microparticles was 
investigated. The encapsulation of DMOG into PLGA MPs proved challenging due to the 
amphiphillic nature of DMOG. More success was found with IOX2 which is hydrophobic 
and allowed for successful encapsulation into PLGA MPs. It was hypothesized that 
sustained delivery of IOX2 in MSC spheroids via MP incorporation would further 
enhance the angiogenic potential of the MSC spheroids compared to spheroid culture 
alone. The effect of PHDi delivery on angiogenesis was assessed by measuring secretion 
of VEGF in the conditioned media and HUVEC migration assays. The delivery of IOX2 
via first generation microparticles was as effective as soluble treatment, however, the 
formation of IOX2 crystal debris during formation necessitated the formulation of a 
second generation IOX2 MP that was both smaller and did not have crystallized IOX2 
debris. These microparticles, however, had approximately 10 times less IOX2 
encapsulated and ultimately were unable to have an appreciable effect on the VEGF 
secretion of MSC spheroids. This could be optimized in the future through further tuning 
of IOX2 concentration and co-solvent percentage used in the emulsion process to allow 
for improved delivery and a more controlled exposure of IOX2 to MSC spheroids. 
Additional biomaterials could also be investigated to increase encapsulation of IOX2. 
The ability to modulate the hypoxia response of MSC spheroids through IOX2 delivery 
will prolong and enhance the pro-angiogenic secretory response of hypoxic environments 




CHAPTER 1  INTRODUCTION 
 Chronic non-healing wounds are a major healthcare concern in the U.S, especially 
due to the growing diabetic and elderly population. Wound healing is a complex 
biological process that is dependent on cells at the site of injury to signal and recruit 
immune cells, fibroblasts, and endothelial cells in order to rebuild damaged vasculature 
via angiogenesis. MSCs aid in wound healing and revascularization of damaged tissue 
because of their ability to secrete pro-angiogenic cytokines such as VEGF, Interleukin-6, 
hepatocyte growth factor (HGF) monocyte chemotactic protein-1 (MCP-1) and 
transforming growth factor-β1 (TGF-β1) [14] which recruit immune cells and endothelial 
cells to the site of injury to form new blood vessels. Hypoxia is known to be a key 
regulator in the angiogenic response of many cells, including MSCs.  Small molecule 
drugs termed prolyl hydroxylase inhibitors (PHDi) are able to cause a hypoxic response 
in cells and can enhance MSCs ability to facilitate angiogenesis. The objective of this 
project was to investigate and compare the effects of commercially available PHDi on 
pro-angiogenic factor secretion of MSCs. Additionally, since the response to the drugs is 
likely short-lived, a method for prolonged delivery or exposure of PHDi to MSCs was 
investigated. 
Specific Aim 1: Evaluate the pro-angiogenic factor secretion of Mesenchymal 
Stromal/Stem Cells (MSCs) in response to prolyl hydroxylase inhibitors and culture 
format. Hypoxia has been shown to enhance MSCs wound healing and angiogenic 
potential. Multiple small molecule drugs are commercially available that stabilize HIF-1α 
through inhibition of prolyl hydroxylase, the enzyme responsible for hydroxylation of 
HIF-1α leading to its degradation in the presence of oxygen. The three small molecules 
investigated here are DMOG, IOX2, and 3,4-DHB. Thus, a side-by-side comparison of 
the three drugs was performed to determine optimal concentrations that provide the 
highest VEGF secretion, without adversely effecting cell growth. The lasting effects of 
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PHDi on MSCs after PHDi removal was assessed. Additionally, the two best conditions 
were investigated in a 3D culture format to further study the effect of soluble delivery on 
MSCs. It is hypothesized that treatment of MSC spheroids with PHDi will have a greater 
effect than treatment of PHDi on monolayer cultured MSCs due to a known effect of 
spheroid culture on the secretion of paracrine factors[11].  
Specific Aim 2: Encapsulate DMOG and IOX2 in PLGA Microparticles for delivery 
to MSC Spheroids for enhancement of pro-angiogenic factor secretion. Due to the 
short-term effects of soluble treatment with DMOG and IOX2, a method to prolong 
delivery of the drug when transplanting MSC spheroids in a clinical setting would be 
beneficial. Incorporation of microparticles containing PHDi into MSC spheroids would 
allow for the sustained delivery of PHDi from within the spheroid as opposed to a soluble 
pre-treatment in culture media. The objective of this study is to encapsulate DMOG and 
IOX2 in PLGA microparticles and assess effects on angiogenic factor secretion when 
incorporated into the MSC spheroids. It is hypothesized that PHDi microparticle 
incorporation will cause similar pro-angiogenic responses as soluble treatments as 
determined by VEGF secretion, HUVEC migration, and endothelial scratch assays. 
Motivation and Significance: MSCs have shown promise in animal models of wound 
healing and angiogenesis largely through modulation of the immune response and 
promotion of angiogenesis leading to improved vascularization of the wound bed. 
However, there are still challenges for their successful clinical translation. First, 
engraftment and persistence of single cell MSCs is poor which limits the time that MSCs 
can secrete paracrine factors at the site of injury. Transplantation of spheroids, however, 
appears to be a promising method for enhancing engraftment and improving therapeutic 
efficacy through higher paracrine factor secretion. Enhancement of the paracrine factor 
secretion of MSC spheroids through PHDi treatment may further improve MSC spheroid 
therapeutic efficacy during the course of treatment. 
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CHAPTER 2  Wound healing 
2.1 Wound healing 
2.1.1 Challenges and Unmet Clinical Needs of Wound healing 
Approximately 6.5 million people in the U.S suffer from chronic non-healing wounds 
each year. These wounds are most common in diabetics and the elderly and are largely 
pressure ulcers or diabetic foot ulcers. The elderly accounts for approximately 72% of 
pressure ulcers noted in hospitals[15]. Pressure ulcers are caused by pressure or shearing 
forces being applied to the skin for prolonged period of times leading to a decrease in 
oxygen tension, tissue necrosis and ischemic reperfusion injury[16]. Diabetic foot ulcers 
are the other main cause of chronic wounds. Approximately 25% of diabetic patients will 
develop foot ulcers, and 12% of these cases will lead to foot amputation. To further 
exacerbate this issue, approximately 50% of amputees will develop a foot ulcer in the 
surviving foot within 5 years[17]. Typical treatments for non-healing wounds are treated 
using the TIME methodology (Tissue removal, Infection prevention, Moisture rebalance, 
Epithelialization promotion)[18]. However, many wounds are not responsive to this 
therapy and necessitate more advanced therapies in order to successfully revascularize 
the wound bed. This is thought to be due to phenotypic abnormalities in the cells of 
diabetic or elderly patients that include a decrease in responsiveness to growth factors, 
reduced migration, and lack of response to hypoxia[19], [20]. These abnormalities 
impede ECM deposition and formulation of granulation tissue ultimately impairing the 
wound healing process. Thus more advanced therapies are necessary to treat non-healing 
wounds. 
2.1.2 Wound Healing Process 
The wound healing process is a complex series of events broken into three main stages: 
inflammation, proliferation, and remodeling. When an injury occurs it disrupts blood 
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flow to the local vasculature, causing low oxygen tension in those tissues and triggering a 
hypoxic cellular response to begin the wound healing process. A blood clot forms 
through platelet adhesion to the damaged vasculature and acts as a scaffold for growth 
factors and cells migrating in response to the damage. 
2.1.2.1 Inflammation 
The acute inflammatory stage of wound healing typically lasts three days[21]. Growth 
factors secreted by the local damaged tissue in response to hypoxia, recruit inflammatory 
cells to the site of injury. Neutrophils are a major immune cell recruited at the early 
stages and are critical for protease secretion and phagocytosis for debridement of the 
wound and to kill bacteria. Neutrophils are recruited by IL-8 and MCP-1[22] and after 
approximately two days, the neutrophils are phagocytosed by macrophages recruited to 
the wound site by molecules such as RANTES, MCP-1, and MIP-1α[3][23]. Sources of 
the chemotactic factors responsible for macrophage recruitment include platelets trapped 
in the blood clot, keratinocytes, fibroblasts, and leukocytes[22]. Macrophages become 
activated and secrete potent growth factors such as VEGF, TGF-β, bFGF, and PDGF 
which are involved in ECM deposition and cell proliferation[24].   
2.1.2.2 Proliferation and Angiogenesis 
The proliferative phase occurs approximately three to ten days after wounding. Local 
keratinocytes and epithelial stem cells are involved in the re-epithelialization process. In 
order to facilitate full re-epithelialization, angiogenesis must occur to restore blood flow 
and oxygen to the proliferating cell populations. Secretion of growth factors such as 
VEGF, PDGF, and bFGF activate endothelial cells (ECs) in existing vascular networks. 
ECs dissolve the basal lamina to allow for migration into the wound site via a process 
known as sprouting. As the ECs migrate, cells at the leading edge secrete MMPs that 
breakdown tissue to allow for continued migration and proliferation. The resulting 
network of sprouts eventually interconnect and form vessels. Pericytes are recruited to 
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provide further maturation and support to the vessel walls for arterial or venule 
formation. Once blood flow is restored the process of angiogenesis is considered 
complete.  
2.1.2.3 Remodeling  
The final stage of wound healing is remodeling and scar formation and can last up to two 
years. In this phase fibroblasts will gradually replace ECM components such as  
fibronectin and hayaluronic acid with a collagen matrix. MMPs are secreted by 
fibroblasts in addition to macrophages and endothelial cells and aid in the remodeling 
process. Myofibroblasts at the wound edge contribute to wound contraction allowing for 
wound closure. The collagen matrix is disorganized at first, but will eventually become 
oriented. This process if highly regulated by PDGF, TGF-β, and FGF[25].  
2.1.3 Pathological Wound Healing 
While most wounds are typically healed within two weeks, diabetic and elderly patients 
often suffer from chronic non-healing wounds that are unable to repair themselves for 
months even with treatment from hospitals. This is typically due to an excessive and 
chronic inflammatory phase, infections, or a loss of response to reparative stimuli such as 
hypoxia that results in insufficient revascularization and wound closure[18][26].  
2.1.4 Current Advanced Treatments for Wound Healing 
Autologous or engineered skin grafts and growth factor treatments are two of the more 
common current advanced treatments. A full-thickness portion of patient’s skin can be 
removed from a non-wounded area and transplanted to the site of the wound. It is critical 
that there is no infection present, sufficient hemostasis, and removal of pressure at the 
wound site for the weeks following the grafting procedure. Tissue-engineered human skin 
equivalents can also be used such as Integra or Dermagraft[27][28]. These skin 
substitutes consist of cross-linked collagen and glycosaminoglycans that mostly serve to 
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transiently close the wound to allow for the patients cells to migrate and subsequently 
reject, degrade, and rebuild its own collagen matrix for successful wound healing.  
 
Many growth factors are known to play critical roles in wound healing although 
successful clinical translation has been limited[19]. Vascular Endothelial Growth Factor 
(VEGF) is critical for endothelial cell recruitment and angiogenesis and has been proven 
in animal and in vitro models to improve wound healing[29]. However, clinical trials 
have shown limited efficacy. This could be due to multiple reasons, including the need to 
deliver supraphysiological doses due to the low residency time at the wound site. 
Additionally, short half-life of growth factors and high costs can be an issue. PDGF-bb is 
the only clinically proven growth factor to improve wound healing in clinical trials[30], 
[31]. However, recent studies have also shown concern of an increased cancer risk in 
cases of recurrent treatments with PDGF-bb, since many patients with chronic non-
healing wounds may have multiple in the span of one year[32]. 
 
2.1.5 Mesenchymal Stem Cells and Wound Healing 
MSCs are known to be involved in wound healing and are currently being investigated 
for treatment of chronic wounds in diabetic patients[33], [34]. The use of MSCs is a 
promising clinical therapy due to evidence that allogeneic MSCs are well tolerated by the 
body. This is thought to be due to the lack of expression of co-stimulatory molecules B7-
1, B7-2, CD40, and CD40 Ligand which may prevent the activation of alloreactive T 
cells [35]. The mechanism of action of MSCs in wound healing is thought to be three 
fold. First, MSCs secrete anti-microbial factors such as LL-37 that help to reduce 
infection[36]. Second, MSCs are able to modulate the immune response to prevent a 
chronically inflamed environment which is known to inhibit wound healing. Third, MSCs 
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are capable of promoting angiogenesis through secretion of paracrine factors such as 
VEGF and inducing cell migration and proliferation to the site of the wound.  
2.1.5.1 Antimicrobial 
Bacterial infection can be a major barrier in successful wound healing. MSCs aid in 
bacterial clearance not only through their effects on immune cells responsible for clearing 
bacteria, but also through secretion of the anti-microbial peptide LL-37[36] which is 
known to directly kill microorganisms. This is important since persistence of infection in 
the wound bed leads to the prolonged presence of neutrophils and may further exacerbate 
a chronic non-healing wound. 
2.1.5.2 Modulation of Immune Response 
MSCs have been shown to modulate the immune response in a chronic inflammatory 
environment and are currently being investigated for treatment of diseases such as 
Crohn’s disease[37] and multiple sclerosis[38] that are characterized by chronic 
inflammation. MSCs modulate the immune response by affecting multiple immune cell 
types. IFN-gamma and TNF-α at the wound site stimulate the MSCs to secrete PGE2 
which effects the cytokine secretion of dendritic cells, T-cells, and natural killer cells 
causing the immune cells to increase secretion of anti-inflammatory molecules and 
decrease secretion of pro-inflammatory molecules[39]. The resulting change in cytokine 
environment is critical for wound healing to progress from the inflammation phase to the 
proliferative phase. Prolonged inflammatory phases are a major cause of chronic non-
healing wounds[18].  
2.1.5.3 Angiogenesis 
Angiogenesis is critical for successful wound healing so that blood flow and oxygen can 
be returned to the tissue. Damaged keratinocytyes at the site of the wound secrete the 
cytokine CCL21 that recruit MSCs to the site of injury to aid in the repair of blood 
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vessels[40]. Additionally, MSCs at the site of a wound have been shown to secrete 
paracrine factors such as VEGF and FGF that recruit endothelial cells for growth of new 
blood vessel walls[41]. MSCs improve functional hemodynamics and functional vascular 
regeneration in a chronic ischemic skin flap model through pro-angiogenic paracrine 
factor secretion[42]. Grafting of MSC spheroids into ischemic tissue has been shown to 
increase new blood vessel formation and improve limb survival[11]. Direct cell contact 
with endothelial progenitor cells and MSCs has also been shown to increase 
differentiation to endothelial cells from both cell types in an in vitro tube forming 
assay[43]. Thus, the mechanisms of MSCs involvement are through both paracrine factor 
secretion, but also as support cells to regenerate the vasculature.  
2.2 Hypoxia and Angiogenesis 
2.2.1 Hypoxia 
The hypoxia response of cells controls many biological processes including 
revascularization of damaged tissue, tumor growth, wound healing, and cell metabolism. 
Additionally, hypoxic culture of MSCs contribute to maintenance of stem cell potency in 
vitro which is thought to be due to a better recapitulation of the bone marrow niche in 
which MSCs can reside in the body.[44] which. Cells are able to quickly respond to 
hypoxia by transcription of hypoxia responsive genes by Hypoxia Inducible Factor(HIF).  
2.2.2 Hypoxia Inducible Factor Signaling Pathway 
The HIF signaling pathway is the main regulator of effects due to lack of oxygen. The 
pathway consists of HIF-1,2,and 3 with HIF-1 having the most prominent effect and thus 
is discussed in more detail below. HIF-1 is a heterodimer consisting of an oxygen 
responsive HIF-1α subunit and an oxygen independent HIF-1β subunit. When oxygen is 
present, HIF-1α is hydroxylated by prolyl hydroxylase 2 (PHD2), which requires oxygen, 
Fe2+, and 2-oxoglutarate as co-substrates for successful hydroxylation. The hydroxylation 
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of proline residues 402 and 564 marks HIF-1α for degradation by the 26s proteasome 
through its interaction with the β domain of the Von Hippel-Lindau tumor suppressor 
protein (pVHL) causing it’s ubiquitination by the pVHL-E3 ligase complex.   
 In hypoxic conditions, PHD2 lacks oxygen as a co-substrate and cannot 
hydroxylate HIF-1α for degradation, leading to the accumulation of HIF-1α in the 
nucleus where it dimerizes with HIF-1β. There, a complex is formed with p300/Creb 
binding protein which binds to Hypoxia Response Elements (HREs) and promotes the 
transcription of hypoxia response genes such as vascular endothelial growth factor 
(VEGF), heme oxygenase-1 (HO-1), erythropoietin (EPO), inducible nitric oxide 
synthase (iNOS), glucose transporter protein-1 (Glut-1), insulin-like growth factor 2 
(IGF-2), endothelin 1, and transferrin, among others. These genes are involved in the 
regulation of angiogenesis, proliferation, survival, and glucose transport.  
2.2.3 Methods to perturb the HIF-1α System 
Prolyl Hydroxylase can be inhibited through multiple methods in normoxic conditions. 
One of the oldest methods used is to disrupt the balance of Fe2+ either by use of an iron 
chelator such as Deferoxamine (DFO) or Cobalt Chloride, which competitively inhibits 
iron. As mentioned previously, iron is a co-substrate needed for PHD to become 
activated, thus iron effectors are quite effective at inhibiting PHD. However, iron is a 
necessary cofactor in many biological processes so the lack of specificity and the risk of 
off-target effects is not desirable.  
Another method for inhibiting PHDs is through the use of 2-oxoglutarate analogs 
such as L-Mimosine (L-Mim), Dimethyloxalyl-glycine (DMOG), 3,4-Dihydroxybenzoate 
(3,4-DHB), and N-[[1,2-dihydro-4-hydroxy-2-oxo-1-(phenylmethyl)-3-
quinolinyl]carbonyl]-glycine (IOX2). However, 2-oxoglutarate analogs also have 
drawbacks because they may inhibit other 2-oxoglutarate oxygenases. Importantly, 
histone demethylases are 2-oxoglutarate dependent, which could cause unintended effects 
 10 
on the epigenetics of the cells treated. DMOG is one of the most commonly used 2-
oxoglutarate analogs. However, Chowdhury et al found that DMOG was less potent than 
IOX2 with relative IC50 values of 5µM and 0.022µM respectively. Also, increase in 
HIF-1α appeared to be due to both inhibition of PHD2 and Factor inhibiting HIF (FIH) 
which can be distinguished by asparingyl hydroxylation of HIF-1α rather than prolyl 
hydroxylation of HIF-1α. Additionally, it was determined that IOX2 was 2-5000 times 
more selective for PHD2 than histone demethylases assayed. The authors concluded that 
IOX2 was the ideal PHD inhibitor since it was commercially available, highly potent, and 
most importantly more selective towards PHD2 than the histone demethylases tested[10].    
2.2.4 Effects of hypoxia on MSCs 
The effects of hypoxia on the differentiation potential of MSCs in vitro has been well 
studied. Yang et al found that MSCs cultured in hypoxia or treated with the iron chelator 
DFO exhibited decreased osteogenic potential[45]. A more recent report studied the 
effect of hypoxia and DFO or DMOG on human primary MSCs and found that hypoxia 
and both PHDi promoted osteogenesis but suppressed adipogenesis[46]. The 
discrepancies in the osteogenic potential results may be due to differences in the systems 
used for hypoxic culture, or variations in donor MSCs. Hypoxia has also been found to 
aid in the maintenance of potency and prevention of senescence of MSCs during long 
term culture[44].  
Hypoxic pre-conditioning of MSCs has been shown to affect the migration and 
engraftment of MSCs. Hung et al found that pre-conditioning of MSCs in hypoxia led to 
increased expression of CXC3RI and CXCR4, both of which are known to be important 
for modulating MSC migration to sites of injury[47]. The exposure to DFO was also able 
to increase expression of the receptors. Hypoxic pre-conditioned MSCs were mixed with 
normoxic MSCs and competitively engrafted into a chick embryo. Hypoxic MSCs 
engrafted preferentially and incorporated into the tissues of the developing embryo 
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demonstrating that hypoxic pre-conditioning aids in the homing and engraftment of 
MSCs[47].  Rosova et al also found that hypoxic preconditioning improved MSC cell 
migration and increased Akt activation. Additionally, hypoxia pre-treated MSCs 
accelerated restoration of blood flow to the hind limbs in a hind-limb ischemia model[4].  
Changes in paracrine factor secretion from MSCs in response to hypoxia have 
been observed. Kinnaird et al found that VEGF, FGF-2, IL-6, PlGF, and MCP were 
secreted at higher levels under hypoxic culture at 1% O2 than normoxic culture[41]. 
Although there have been multiple studies investigating the effects of various PHDi on 
MSCs and many other cell types, the use of PHDi as an engineering tool for potential 
therapies has not been thoroughly investigated. Pre-conditioning of MSCs in hypoxia 
before transplantation has been shown to have lasting effects on cell migration up to 14 
hours after treatment[4].  While this may be useful for clinical applications in which the 
MSCs are needed to home to the site of injury- wound healing applications would likely 
involve direct application of the MSCs for longer than 14hours and thus may require 
methods to allow for longer term exposure to the PHDi to maintain effects.  
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CHAPTER 3  Effect of Prolyl Hydroxylase Inhibitors on the Secretion of Angiogenic 
Factors by Mesenchymal Stromal/Stem Cells 
3.1 Introduction 
Prolyl Hydroxylase inhibitors are commonly used to increase HIF-1α expression in 
many cell types. Commonly used PHD inhibitors are DFO, an iron chelator, and the 2-
oxoglutarate analogs, DMOG and 3,4-DHB. Pharmaceutical companies, however, have 
moved away from these molecules due to their lack of specificity and have developed 
drugs that claim to be highly specific for PHDs. The pharmaceutical company Glaxo 
Smith Kline, currently has clinical trials ongoing with a PHDi molecule GSK1278863, 
for treatment of anemia, chronic kidney disease, and peripheral artery disease[48]. The 
use of more specific PHD inhibitors is important to decrease risks of off-target effects 
such as inhibition of histone demethylases which are in the same family of enzymes as 
PHD[10].  A recent study found that the PHDi, IOX2, was more potent than DMOG and 
is commercially available. While IOX2 has been characterized in other cell lines, it has 
not been thoroughly investigated in MSCs. It has been shown to affect MSCs in a similar 
manner as hypoxia in terms of autophagy of MSCs, however, paracrine  factor secretion 
was not assessed, nor effects on wound healing or angiogenesis[49]. Due to the potential 
advantages IOX2 may have due to its increased potency and high selectivity, IOX2 was 
chosen as a candidate to investigate further in this study.   
The culture of MSCs as three dimensional spheroids may have multiple advantages 
to single cell culture. First, spheroid culture increases the immunomodulatory and 
angiogenic paracrine factor secretion of MSCs compared to monolayer[7][12]. 
Additionally, MSC aggregates have been shown to have improved cell retention and 
survival when delivered in vivo[50]. This is thought to be due to a pre-conditioning to 
local hypoxia by cells in the interior of the spheroid, thus conditioning the spheroids to 
better tolerate ischemic environments in vivo[11]. The maintenance of native ECM and 
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cell-cell contacts are also contributing mechanisms in increased cell survival and 
enhanced paracrine factor secretion of MSC spheroids compared to single cells[51].  
The first objective of this study was to examine the effects of two common PHD 
inhibitors DMOG and 3,4 –DHB and the more specific PHD inhibitor, IOX2, on the 
angiogenic factor secretion of MSCs. Second, the effect of PHDi treatment on MSC 
spheroids formed by forced aggregation will be assessed. It is hypothesized that this will 
further enhance the pro-angiogenic factor secretion of MSCs due to previous literature 
that both spheroid formation and hypoxic culture enhance MSC angiogenic factor 
secretion. 
3.2 Methods 
3.2.1 Mesenchymal Stromal/Stem Cell Culture 
Human bone marrow derived Mesenchymal Stem Cells were obtained from the Texas 
A&M College of Medicine Institute for Regenerative Medicine and cultured according to 
established protocol[52]. Approximately 1 x 106 cryopreserved MSCs of a passage 
number no greater than four, were plated onto a 150mm tissue culture dish in 20 mL of 
MSC complete media (Minimum Essential Media, Alpha, [Mediatech, Inc., Manassas, 
Va, USA], 16.5% Fetal Bovine Serum [HyClone, Logan, UT, USA], 2 mmol/L L-
glutamine [Mediatech, Manassas, VA, USA], 100 U/mL penicillin and 100 µg/mL 
streptomycin [Mediatech]) and incubated overnight(37°C, 5%CO2). The day after 
thawing, cells were rinsed with PBS and detached from the plate using 0.25% Trypsin 
and 2.21mM ethylenediamine tetraacetic acid in Hank’s Buffered Salt Solution 
(Mediatech). Equal volumes of MSC complete media were added and the dissociated 
cells were counted using a hemacytometer. Cells were plated onto 150mm tissue culture 
dishes at a density of 60 cells/cm2 in 20mL of MSC complete media. Cells were fed by 
complete media exchange every three days until cells reached approximately 70% 
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confluency. Cells were then passaged using trypsin and used for subsequent experiments. 
Monolayer experiments were plated at a density of 5,500cells/cm2 in 24-well plates. 
3.2.2 Spheroid Formation and Culture 
MSC spheroids were formed using forced aggregation into agarose micro-wells to allow 
for the high-throughput generation of homogeneously sized spheroids. Briefly, 6 x 105 
human MSCs were added to 24-well micro-well inserts consisting of approximately 1200 
wells that are 400µm in size to form ~500 cell spheroids. The plates were spun at 200g 
for 5 minutes and then incubated for 18 hours (37°C, 5% CO2) before being gently 
pipetted using wide bore pipette tips and transferred to 100mm bacteriological grade petri 
dishes.  Approximately 600 spheroids were transferred per plate and cultured in 10mL 
MSC complete media (described above) in suspension culture on an orbital rotary at 
65rpm for up to 4 days.  
3.2.3 Treatment of MSCs with Prolyl Hydroxylase Inhibitors 
Dimethyloxalyl Glycine(DMOG, R&D Systems), 3,4-Dihydroxybenzoate(AKA 
Protocatechuic acid ethyl ester, Sigma), and IOX2 (Tocris) were dissolved in DMSO at a 
concentration of 100mM, 137mM, and 21mM respectively. Stock solutions were added 
directly to culture media at appropriate concentrations. For vehicle controls, equal 
volumes of sterile DMSO were added to the media.    
3.2.4 Conditioned Media Collection 
At day four of culture, spheroids and media were transferred to a 15mL conical tube 
where spheroids were centrifuged (100g, 5min). Conditioned media was collected and 
stored at -20°C until further analysis. VEGF secretion was determined using a DuoSet 
ELISA kit for human VEGF (R&D systems). Spheroids were rinsed with PBS, pelleted, 
and then frozen and stored at -80°C overnight until cell number was determined using a 
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CyQUANT Cell Proliferation Kit (Life Technologies) according to the manufacturer’s 
protocol.  
3.2.5 Human Cytokine Antibody Array 
A membrane based human cytokine antibody array (Abcam, ab133998) containing 80 
cytokines involved in immune response and angiogenesis was performed according to 
manufacturer’s protocol. Briefly, membranes were blocked with the blocking buffer 
(30min, RT), and then 1mL of conditioned media (pooled from four samples) was added 
to the membrane for overnight incubation at 4°C under gentle shaking. Membrane was 
washed thoroughly with wash buffer I and wash II before biotin-conjugated anti-
cytokines were added and incubated (2h, RT). Membranes were washed as described 
previously and incubated with HRP-conjugated streptavidin (diluted 1:1000, 2h, RT). 
After washing, the membranes were blot-dried and incubated with the detection buffer (2 
min, RT), and then were imaged using ODYSSEY Infrared Imaging System (LiCor, 
Lincoln, NE). Intensity of individual dots was quantified by densitometric analysis using 
ImageJ software (National Institutes of Health). The membrane incubated with sample 
collected from monolayer vehicle group was assigned as reference membrane. The 
normalized signal density of each dots was then calculated using the formula: 
X(Ny)=X(y)*P1/P(y), where P1=mean density of Positive control spots on reference 
array; P(y)=mean signal density of Positive control spots on Array “y”; X(y)= signal 
density for spot “x” on array for sample “y”, and X(Ny)=normalized signal intensity for 
spot “X” on array “y”. A complete list of cytokines included on the array are found in the 
appendix (A1).  
3.2.6 Statistical Analysis 
Statistical analysis was performed using Prism (GraphPad, Inc). Data is represented as 
mean +/- standard error (n=4, unless otherwise stated). One-way or two-way Analysis of 
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Variance coupled with Tukey’s post-hoc test was used to determine statistical 
significance. P-values less than 0.05 were considered significant. 
3.3 Results 
3.3.1 Effects of various small molecule PHDi on VEGF Secretion of MSCs 
 
A range of concentrations for each PHDi was screened in order to determine appropriate 
dosages and compare the relative potencies of the different inhibitors. VEGF was chosen 
as the primary means of assessment due to its well established activation by the HIF-1α 
pathway and role in angiogenesis. Cell number was quantified as an assessment of cell 
Figure 1:VEGF response of MSCs to three Prolyl Hydroxylase inhibitors: DMOG, IOX2, and 3,4-DHB. 
 MSCs cultured in monolayer for three days were treated with various concentrations of DMOG, IOX2 
or 3,4 DHB. Cell count (A) and VEGF secretion normalized to cell number (B) after treatment with 
PHDi demonstrated varying responses for each respective PHDi. Additional IOX2 dose response was 
performed to determine optimal concentration based on cell number (C) and VEGF secretion (D) in 
response to IOX2. *indicates significantly different to Control (P<0.05). 
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survival and growth. There was no significant decrease in cell number due to PHDi 
treatment with DMOG. However, MSCs treated with IOX2 at 100µM and 250µM had 
almost 40% less cells after three days of treatment (p-value <0.001). The highest dosage 
of 3,4-DHB at 1000µM resulted in 50% fewer cells at day 3 than non-treated MSCs(p-
value <0.001). The VEGF secretion (Figure 1B) by MSCs treated with DMOG was 
increased 13- to 18-fold compared to untreated MSCs, but did not vary significantly over 
the range of DMOG concentrations examined. The VEGF response to IOX2 was 
increased approximately 17-fold at higher concentrations of 100µM and 250µM, which 
were also the two groups with significantly decreased cell numbers. An additional range 
of IOX2 concentrations were examined in order to determine an effective concentration 
Figure 2: The effect of PHDi on MSC morphology. MSCs treated with DMOG at 100µM(B), 
250µM(C), and 500µM (D) looked similar to MSCs that were not treated with PHDi (A). The 
morphology of IOX2 treated MSCs appeared normal for 10µM(E), 25µM(F) and 50µM(G), but 
100µM IOX2 (H) appeared sparse. 3,4-DHB cells (I-L, 100, 250, 500, 1000µM respectively) had 
normal morphology but were more sparse than the control.  
 18 
that did not have a negative effect on cell growth. IOX2 concentrations between 10µM 
and 90µM were assesed. This study revealed an optimal concentration of 60µM for IOX2 
due to a peak in the VEGF response at 23ng VEGF/million cells (Figure 1D) and no 
significant decrease in cell number (Figure 1C). In contrast, the highest concentration of 
3,4-DHB stimulated a 29-fold increase in VEGF secretion, however, this was 
accompanied by a 3-fold reduction in cell number (Figure 2L). 
3.3.2 Transient Response to PHDi 
To assess the persistence of the effects of PHDi on VEGF secretion, PHDi was either 
included or omitted from the culture media at day 3 of feeding and changes in VEGF 
level were assessed at day 6. (Day 6+ or Day 6-, respectively) for MSCs previously 
treated with 100µM DMOG, 50µM IOX2, and 1000µM 3,4-DHB. It was evident that the 
omission of PHDi from culture media caused VEGF levels to be attenuated indicating a 
Figure 3: Transient Response to PHDi. Persistence of VEGF response was assessed by removal of 
PHDi from the culture media at Day 3, and testing for VEGF in Day 6 conditioned media. 
Concentrations of 100µM, 50µM, and 1000µM are shown for DMOG, IOX2, and 3,4-DHB 
respectively. 
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transient increase in VEGF secretion by MSCs in response to PHDi in all three PHDi 
tested. 
 
3.3.3  Effect of DMOG and IOX2 on VEGF secretion of MSC spheroids 
DMOG and IOX2 were chosen for further investigation into their effects on MSCs when 
cultured as three dimensional spheroids. As observed previously, culturing of MSCs as 
spheroids instead of adherent monolayers induced a six-fold increase in VEGF secretion 
(per cell) in the absence of PHDi or hypoxic conditions(Figure 4). The addition of PHDi 
to the culture media of MSC spheroids led to an approximate 2-fold increase for both 
100µM DMOG and 60µM IOX2.  These results demonstrate that treatment of MSCs with 
PHDi augments secretion of VEGF when cultured as spheroids rather than monolayer.   
3.3.4 Semi-Quantitative screen of cytokines affected by IOX2 
A membrane based antibody array analyzing conditioned media from MSCs treated with 
60µM IOX2 in monolayer or spheroid culture (Figure 5A) revealed at least a 10% 
increase in cytokine concentration in 61 and 68 of the 80 cytokines assayed for 
monolayer and spheroid treated cells, respectively. Additionally, levels of two cytokines, 
IL-8 and MCP-1 were decreased upon IOX2 treatment in both monolayer and spheroid 
Figure 4: Effects of PHDi on the VEGF secretion of MSC Spheroids. VEGF secretion of MSCs 
in response to DMOG(A) or IOX2(B) was assessed when cultured either as monolayer or 
spheroids. ** indicates statistically different to no treatment (p-value <0.01). ††† indicates 
statistically different to monolayer.   
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cultures. To examine the most responsive cytokines, a threshold of a 2 fold change from 
no treatment was established (Figure 5B). Nine cytokines had 2-fold or higher increase in 
secretion upon IOX2 treatment and included IL-10, TARC, VEGF, Eotaxin, IGFBP-2, 
IGF-BP3, NT-3, Leptin, and TGF-β1.  Also of note are cytokines that responded 
differently upon IOX2 treatment across the different culture platforms. RANTES was 
increased upon IOX2 treatment in spheroid culture but was unaffected upon treatment 
with IOX2 in monolayer culture relative to untreated MSCs. The relative levels of GRO 
in conditioned media of IOX2 treated spheroids decreased whereas the levels slightly  
increased upon treatment in monolayer culture. 
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Figure 5: A semi-quantitative membrane based antibody array screened for 
80 human cytokines present in MSC conditioned media (A). Densitometry 
analysis normalized to positive controls revealed that secretion of at least 75% 
of the cytokines was increased with IOX2 treatment. Cytokines that were 
upregulated by at least two fold are shown (B). 
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3.4 Discussion 
DMOG, IOX2, and 3,4-DHB were all able to increase the VEGF secretion of MSCs 
in monolayer culture. However, upon removal of PHDi treatment, VEGF secretion was 
attenuated suggesting the presence of PHDi is necessary to maintain the effect on VEGF 
secretion. DMOG and IOX2 treatment in spheroid culture further increased VEGF 
secretion by 6-fold. A semi-quantitative antibody array detected increased levels of the 
majority of the 80 cytokines screened in the conditioned media of IOX2 treated MSCs 
relative to untreated MSCs for both monolayer and spheroid culture many of which were 
related to angiogenesis.  
 The differences observed in cell growth, morphology, and VEGF secretion of 
MSCs in response to DMOG, IOX2, and 3,4 DHB is interesting to note, and likely due to 
differences in specificity of each PHDi. Previous reports in other cell lines have 
demonstrated low responsiveness of cells to 3,4-DHB[53]. The results here found an 
increase in VEGF secretion to 3,4-DHB was only apparent at the highest concentration of 
1000µM. However, this concentration also caused reduced cell number and a change in 
cell morphology, rendering this treatment undesirable. Thus it was concluded that 3,4-
DHB should not be investigated further. 
Cytotoxicity has not been reported at DMOG concentrations of up to 1 mM and 
activation of HIF-1α can be achieved at as low as 100µM[9], [54]. The concentrations of 
DMOG examined here fall well within that range and concentrations between 100 and 
500µM DMOG were effective at producing an increase in VEGF secretion, while not 
effecting cell growth and survival. DMOG is a non-selective PHDi and may also work 
through inhibition of the enzyme factor inhibiting HIF (FIH). Although DMOG is non-
specific it is effective at inducing an increase in VEGF secretion across a large effective 
range before having an effect on cell number, which could be beneficial in 
pharmaceutical applications. However, IOX2 is more potent than DMOG with an  IC50 
250 fold lower than DMOG, and more specific for PHD over other 2-oxoglutarate 
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dependent enzymes such as histone demethylases[10]. IOX2 is one of the most potent 
inhibitors of PHD commercially available and thus the effects of IOX2 on paracrine 
factor secretion of MSCs was assessed further through a semi-quantitative screen that 
compared relative levels of cytokines in MSC conditioned media. This study 
demonstrated that the small molecule drug candidate IOX2 enhances the secretion of a 
multitude of cytokines commonly involved in wound healing. 
The cytokine array results support the hypothesis that IOX2 will lead to increased 
paracrine secretion of factors implicated in angiogenesis. In addition to VEGF, the 
secretion of 8 other cytokines was increased by two-fold or more which include: IL-10, 
TARC, eotaxin, IGFBP-2, IFGBP-3, NT-3, Leptin, and TGF-β3. Of specific interest, IL-
10 was increased almost 3 fold with PHDi treatment. IL-10 is an anti-inflammatory 
cytokine and has been shown to be critical in wound healing for its role in preventing 
neutrophil infiltration into the wound[55]. Additonally, IL-8 was decreased upon IOX2 
treatment by approximately 30% which may also lead to decreased neutrophil 
recruitment since IL-8 is a known chemoattractant to neutrophils[22]. This is important 
because the persistence of high amounts of neutrophils is indicative of a chronic non-
healing wound environment, thus PHDi treatment may improve chronic wound healing 
through not only increasing angiogenic paracrine factor secretion but also decreasing 
neutrophil infiltration.  
An increased secretion of TARC by IOX2 treated MSCs was observed in the 
antibody array. TARC is a chemokine that serves for the recruitment and migration of T-
helper type II cells which are known to secrete anti-inflammatory cytokines IL-4, IL-10, 
and IL-13 [56]. Also, TARC has been shown to induce MSC migration in vitro[40]. 
Eotaxin, a chemoattractant known to cause the infiltration of eosinophils, was also 
present in the IOX2 treated MSCs. An established link between eotaxin and angiogenesis 
has been established in previous studies through an increase of endothelial cell migration 
in vitro as well as CAM assays and matrigel plug assays[57]. 
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IGF binding proteins are known to be involved in angiogenesis. IGFBP-2 has been 
studied heavily in the cancer field, linking it with tumor angiogenesis and enhancement 
of VEGF gene promoter activity in neuroblastoma cells[58]. Additionally IGFBP-2 
increases with HIF-1α expression so it is not surprising that it is upregulated in IOX2 
treated MSCs since IOX2 acts by stabilizing HIF-1α[59]. IFGBP-3, was also upregulated 
in IOX2 treated MSCs and has been shown to induce angiogenesis both in vitro in tube 
formation assays and in vivo wound healing studies[60].  
The VEGF secretion of MSCs after PHDi was removed from the culture media 
revealed a transient response to PHDi, with VEGF levels returning close to basal levels at 
72 hours. There is limited literature studying the lasting effects of PHDi on paracrine 
factor secretion. Studies have shown, however, functional differences in cells that have 
been pre-conditioned by hypoxia or PHDi approximately 18 hours after pre-
conditioning[4], [61]. The results here suggest that an increase in paracrine factor 
secretion is transient after PHDi pre-conditioning.  
 Overall, the results here demonstrate that both DMOG and IOX2 are promising 
candidates for enhancing the pro-angiogenic factor secretion of MSCs. However, since 
the increase in VEGF secretion is attenuated after PHDi removal simple pre-conditioning 
of spheroids in PHDi may not be the most effective method for preparing MSC spheroids 
for wound healing therapies. The ability to prolong the enhancement of paracrine factor 
secretion of MSC spheroids would likely improve the therapeutic efficacy of MSC 
spheroids to lead to improve wound healing of chronic non-healing wounds.  
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CHAPTER 4  Localized Delivery of PHDi to MSC spheroids via Microparticles for 
Enhanced Angiogenic Factor Secretion of MSCs 
The ability of PHDi’s to enhance the angiogenic properties of MSCs appears to be a 
promising approach for increasing the potential therapeutic efficacy of MSC spheroids 
for wound healing. However, the short-lived effects of pre-treating MSCs with PHDi 
added to culture media is likely not ideal since wound healing is a relatively long process 
that takes approximately 2 weeks to complete. Warnecke et al studied the effects of three 
PHDi: L-Mim, 3,4-DHB, and S956711. When delivered systemically it was found that L-
Mim and S956711 caused an increase in HIF-1α expression in the kidneys but nowhere 
else examined. When injected repeatedly into a rat sponge model there was a strong 
increase in invasion of vascularized tissue into the sponge[5]. Similarly, Ding et al found 
that PHDi treatment improved bone healing capacity of ASCs in a critically sized 
calvarial defect. In this study, ASCs were implanted into the defect using a hydrogel 
composite. Cells were pretreated with DMOG for 24 hours and DMOG was also added to 
the hydrogel. The DMOG hydrogel group outperformed the group with cells engineered 
to overexpress HIF-1α. This was most likely due to the soluble DMOG in the hydrogel 
that had effects on the host response and may have recruited host MSCs or endothelial 
cells to the hydrogel[9]. These studies demonstrate that the use of materials to localize 
the pro-angiogenic effects of PHDi is an important factor for successful clinical use. 
One method to both localize delivery of PHDi and reduce off-target risk is the 
delivery of PHDi via microparticles incorporated within MSC spheroids. Previously, we 
have shown that microparticles can be incorporated into stem cell aggregates to deliver 
12-fold less growth factor compared to soluble delivery and still maintain similar 
effects[13]. Additionally, this may allow for sustained release and exposure of a PHDi to 
MSCs to prolong the pro-angiogenic effects. The objective of this study was to compare 
the encapsulation efficiencies of DMOG or IOX2 into PLGA microparticles and 
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determine the effect of the PHDi microparticles on the pro-angiogenic factor secretion of 
MSCs when incorporated into MSC spheroids. 
4.1 Methods 
4.1.1 PLGA Microparticle Formation 
PLGA microparticles were made using an oil-in-water emulsion technique at a 1:10 ratio 
of oil to water. The oil phase consisted of a 2% (w/v) PLGA solution in dichloromethane. 
Different types of co-solvents were used to dissolve the drug into the oil phase. This 
ranged from 10-40% DMSO and also 12% DMF in order to find conditions that allowed 
for homogeneous microparticle formation and efficient encapsulation. The oil phase 
consisting of either PLGA+cosolvent in DCM or PLGA+Drug+cosolvent in DCM were 
added dropwise to a 2% Poly Vinyl Alcohol(Acros Organics, 88% Hydrolyzed, 
M.W:22,000) solution while being homogenized at 3000rpm for 2 minutes. The emulsion 
was then left on a magnetic stir plate for 3 hours to allow for solvent evaporation. The 
emulsion was centrifuged at 1500 g for 5 minutes and washed three times with water. 
Microparticles were then lyophilized for 48 hours and stored at -20°C until further use. 
4.1.2 Analysis of DMOG or IOX2 concentrations 
DMOG (Figure 6B) was detected using High Performance Liquid Chromatography. This 
was necessary since it was not able to be detected using standard spectroscopy. A 
standard curve was made using known concentrations of DMOG (Figure 6A).  
IOX2(Figure 6D) was detected by reading the absorbance at 330nm and comparing the 
O.D readings of the unknown sample to readings on a standard curve. The optimal 
absorbance reading was found by doing a spectral scan of IOX2 (Figure 6C) and 
determined to be at 330nm (Figure 6C, yellow line). A known amount of microparticles 
were dissolved in the solvent acetonitrile and read against a standard curve. As 
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demonstrated in the spectral scan, the background PLGA did not interfere with the 
absorbance reading of dissolved IOX2 MPs (Figure 6C, Green Triangles). 
4.1.3 Release from PLGA Microparticles 
The release kinetics of IOX2 from PLGA microparticles was determined by resuspending 
1 mg of microparticles in 1 mL of 0.1% BSA Solution (Bovine Serum Albumin, 
Millipore) and incubating at 37°C on a rotisserie. At desired timepoints (3h, 4d, 7d) the 
microparticles were centrifuged at 1500g for 5 minutes and 250µL of supernatant was 
removed and stored at -20°C for later analysis. The volume removed was replaced with 
an equivalent amount of 250µL of 0.1% BSA.  
Figure 6: Small Molecule Detection: DMOG(B) was detected using a standard made 
from HPLC readings(A). IOX2 (D) was detected using absorbance readings at 330nm 
(yellow line), which clearly falls within the spectral range of the molecule(C). 
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4.1.4 Incorporation of Microparticles into MSC Spheroids 
Microparticles were incorporated into MSC spheroids using a modified protocol of the 
forced aggregation technique described previously in chapter 3. After cell centrifugation, 
5.4 x 106 microparticles were added to each micro-well. The plate was subsequently 
centrifuged for a third time before overnight incubation (37°C, 5% CO2) to allow for 
spheroid formation. The spheroids were removed and washed with media twice to 
remove unincorporated microparticles before culture. Efficiency of microparticle 
incorporation was determined by lysing a known number of spheroids in RIPA buffer and 
counting the resulting microparticles on a hemacytometer.  
4.1.5 HUVEC Migration Assay 
Human umbilical vein endothelial cells(HUVECs) were cultured according to Lonza 
protocols using EGM-2MV media (Lonza, EGM-2MV Bullet Kit). Briefly, HUVECS 
were plated at a density of 2,500 cells/cm2 in 5mL of HUVEC media per 25cm2 and 
grown to approximately 70% confluence. Cells were passaged by rinsing the cells with 
PBS and brief exposure to room temperature 0.05% trypsin (approximately 1-3 minutes). 
Cells were collected and centrifuged at 200g for 5 minutes before being used or plated for 
further expansion.  If being used for a HUVEC migration assay, cells were labeled with 
CellTracker Green CMFDA(5-chloromethylfluorescein diacetate; Life Technologies) for 
30 minutes prior to trypsinization. The migration of HUVECs was determined using 
FluorBlok cell culture inserts (8µm pore size, BD Biosciences). Cell culture inserts were 
coated with 10µg/mL fibronectin prior to use for 30minutes and placed into transwell 
companion plates(BD Biosciences). Labeled HUVECs were transferred into 24-well 
inserts at a density of 30,000 cells per insert. Approximately 750µL of basal media 
(EBM, Lonza) was placed in the bottom chamber with MSCs that had previously been 
plated or day 4 spheroids. After 4 hours the cells were read at 485/525nm (Synergy H4 
Hybrid plate reader, BioTek). Prior to reading the wells using a plate reader, transwell 
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inserts were transferred to empty companion plates to allow for fluorescence readings  
that were not disrupted by MSC spheroids or cells disrupting the light path. Relative 
fluorescent intensities readings were used to compare pro-migratory effect of substance 
in the basal chamber.   
4.1.6 HUVEC Scratch Assay 
Human Umbilical Vein Endothelial Cells (Lonza) were grown to confluence in 24-well 
tissue culture plates using EGM-2MV growth media. HUVECs were serum starved 
overnight in basal EGM media before a scratch was made using a pipette tip. The media 
was changed to remove cell debris and replaced with conditioned media. Images were 
take immediately after the scratch and 12 hours post-scratch. The width of the scratch 
was measured using ImageJ.  
4.1.7 Statistical Analysis 
Statistical analysis was performed using Prism(GraphPad, Inc). Data is represented as 
mean +/- standard error (n=4, unless otherwise stated). One-way or two-way Analysis of 
Variance coupled with Tukey’s post-hoc test was used to determine statistical 
significance. P-values less than 0.05 were considered significant.  
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4.2 Results 
4.2.1 DMOG encapsulation into PLGA microparticles 
 
Figure 7: DMOG Microparticle formation. PLGA microparticles (A) and DMOG 
encapsulated microparticles (B) have similar morphology and size. 
The morphology of DMOG encapsulated microparticles appeared normal and 
homogenous in size (Figure 7). However, the amount of DMOG encapsulated into PLGA 
microparticles was very low. One batch of microparticles (approximately 20mg) was 
dissolved in acetonitrile, and was undetectable within the standard curve determined via 
HPLC(Figure 6A). Extrapolation of the small signal would suggest encapsulation of 
approximately 345pmol/mg. This low encapsulation efficiency is believed to be due to 
the amphiphillic nature of DMOG(Figure 6B) which allows DMOG to diffuse into the 






4.2.2 First generation IOX2 Microparticles 
The first generation of PLGA microparticles were made in a small batch with a total 
emulsion volume of 20mL and 40% DMSO as a co-solvent. The IOX-2 was dissolved in 
DMSO at a concentration of 83mM. The resulting IOX2 microparticles contained rod-
like debris (Figure 8B). The particles were larger than expected and spanned a larger 
range than is typical for PLGA MPs produced under similar conditions. The size of the 
PLGA MPs were 5.87µM +/-3.9µm and the IOX2 microparticles were 6.68+/- 4.055µm 
(Figure 8C). The IOX2 microparticles contained 683 nmoles/ mg and released 
approximately 400nmoles over the course of one week (Figure 8D).  
Figure 8: First Generation IOX2 Microparticle Characterization. First generation MPs formed 
were heterogeneous(A) and IOX2 MPs contained rod-like debris (B). The size distribution (C) 
indicated a large variance in the size. Approximately 400 nmoles were released over the course 
of one week(D). 
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4.2.3 Incorporation of first generation IOX2 microparticles into MSC Spheroids 
Microparticles incorporated into spheroids successfully via forced aggregation and 
spheroids appear to be of similar size. PLGA MPs can clearly be seen in the MSC 
spheroids as demonstrated by the dark spots within the spheroids. There appeared to be 
less IOX2 MP incorporation compared to PLGA MP incorporation as evident by the 
smaller areas of dark spots in the MSC spheroids on day 1 (Figure , bottom row). This 
motivated a quantification of microparticle incorporation on day 1 in future studies.  
Additionally, the rod-like debris was evident on day 0 (Figure , top row) but was not 
evident at day 1. This led to the hypothesis that the rod-like debris was actually 
crystallized IOX2. This was ultimately confirmed by dissolving pure IOX2 in DMSO at 
high concentrations and observing the same debris, which did not persist at lower 
concentrations. The presence of IOX2 crystals was deemed unacceptable since it does not 
allow for a large amount of control on dosing of IOX2 as would be desired.  
 
Figure 9: First generation IOX2 microparticle incorporation. Microparticles were incorporated 
using forced aggregation and shown in wells after centrifugation(top row) and out of wells on day 1 
(bottom row). 
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4.2.4 Effect of first generation MP incorporation on VEGF secretion   
MSC spheroids were cultured for 3 days before the conditioned media and cell pellets 
were collected for analysis. The VEGF secretion was assessed via ELISA. The final cell 
number at day 4 of culture was decreased in IOX2 MP treated groups (Figure 10B, p-
value<0.001). Both the soluble IOX2 and IOX2 MP treated groups secreted 
approximately 2-fold more VEGF per cell than the vehicle or PLGA treated groups 
(Figure 10B). The increase in VEGF secretion was encouraging since a significant effect 
in MP treated groups was observed, although, the presence of IOX2 crystals at day 1 
makes it difficult to conclude that this was microparticle mediated and not confounded by 
the presence of IOX2 crystals. Thus, additional microparticle formulations were 
investigated that may lead to more homogeneous microparticle batches that do not have 
excessive amounts of IOX2 crystals in the system.  
 
Figure 10: First Generation MP effects on MSC Spheroids. Cell number (A) and VEGF secretion 
(B) were assessed. ** indicates significantly different than vehicle control (p-value<0.01), *** 
indicates significantly different than vehicle control (p-value<0.001), 
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4.2.5 Second generation microparticle synthesis  
4.2.5.1 Effect of co-solvent percentage 
 
Figure 11: Effect of co-solvent percentage on microparticle formulation. PLGA microparticles made 
from 40% DMSO (A) and 12% DMSO as co-solvents differ in morphology and surface appearance. 
The large variance in size of the first generation microparticles and the irregular surface 
appearance was hypothesized to be due to the high DMSO percentage used as the co-
solvent in the emulsion process which is typically limited to 10-15%. To assess if lower 
co-solvent percentage would lead to more homogeneously sized MPs, a 12% DMSO co-
solvent PLGA microparticle was synthesized. These microparticles appeared to be more 
homogeneously sized than the 40% DMSO co-solvent microparticles and the surfaces 
appeared to be smoother (Figure 11A and 11B). Thus 12% co-solvent was deemed a 
more acceptable co-solvent percentage.  
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4.2.5.2 Choice of co-solvent 
 
Figure 12: Effect of co-solvent on microparticle formation. PLGA microparticles formed with 12% 
DMSO(A) or 12% DMF(B) appear similar in morphology. 
It was evident that IOX2 was not being completely dissolved at the concentration of 
83mM in DMSO even though the solubility in DMSO is reported to be up to 100mM[62]. 
An alternative manufacturer states the solubility of IOX2 to be 14mM in DMSO and 
40mM in DMF[63]. The reported increased solubility motivated the use of DMF as a co-
solvent instead of DMSO. PLGA MPs made using 12% DMF formed successfully(Figure 
12B) and maintained a homogenous morphology similar to the 12% DMSO PLGA 
MPs(Figure 12A). IOX2 was dissolved in DMF at the suggested concentration of 40mM 
and used for microparticle formation at a 12% co-solvent ratio. This final formulation led 
to both homogeneously sized PLGA MPs and successfully removed the presence of the 





4.2.6 Second generation microparticle characterization  
 
Figure 13: Second generation IOX2 microparticle characterization. PLGA MPs (A) and IOX2 MPs 
(B) appeared homogeneous and IOX2 crystals were not observed. The size (C) of the particles was 
less variable than first generation MPs(C). Release of IOX2 from the particles was assessed over the 
course of one week(D).  
IOX2 was successfully incorporated into PLGA microparticles at an amount of 76.4 
nmoles/mg MPs and without the appearance of IOX2 crystals (Figure 13A and B). The 
amount of IOX2 encapsulated was almost 10 fold less than the amount of first generation 
microparticles.  This finding was to be expected, however, due to the lower IOX2 
concentration being added during MP synthesis (83mM compared to 40mM from the first 
generation) and a decrease in co-solvent compound decreasing from 40% to 12%. The 
average size of the PLGA control MPs and IOX2 MPs were 4.7µm +/- 2.2µm and 4.4+/-
1.8µm, respectively (Figure 13C). These were not only smaller but also had decreased 
variance than the first generation microparticles. A release assay over 10 days revealed 
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that after the initial burst release, negligible amount of IOX2 was detected indicating no 
sustained release from the microparticles. (Figure 13D). While the MPs contained less 
IOX2, the smaller size theoretically should improve MP incorporation which was thought 
may compensate for the decreased amount of IOX2 encapsulated per MP. 
4.2.7 Second generation microparticle incorporation  
Second generation microparticles incorporated successfully into the aggregates, leading 
to 6.9x105 and 2.9 x 105 MPs incorporated per plate of spheroids, respectively (Figure C). 
Incorporation of microparticles appears similar to the incorporation observed in first 
generation microparticles (Figure A and Figure , respectively). There was no difference 
in initial cell number incorporated between the microparticle groups (Figure B).  
Figure 14: Second generation microparticle incorporation into MSC spheroids. Microparticles were 
incorporated into MSC spheroids (A) and cultured for 3 days. Cell number(B) and VEGF secretion 
were analyzed(C). ** indicates p-value<0.01 
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4.2.8 Effect of IOX2 MPs on the VEGF Secretion of MSC Spheroids 
The final cell number was similar amongst all the groups, however, approximately 2-fold 
lower than the amount at day 1 (Figure A). VEGF secretion(Figure B) was increased in 
the 60µM soluble treatment group similar to that observed in the first experiment. 
However, unlike the first generation microparticles, incorporation of PLGA MPs or IOX2 
MPs had no effect on the final cell number nor the VEGF secretion of the cells. These 
results indicate that insufficient PHDi was being delivered within the system to elicit an 
increase in VEGF secretion when using the second generation microparticles. 
 
 
Figure 15: VEGF secretion of microparticle treated MSC spheroids. Cell number was similar 




4.2.9 HUVEC migration response to IOX2 treated Spheroids 
 
Figure 16: in vitro Functional Assessment of Pro-Angiogenic effects of treated MSC spheroids. A 
HUVEC migration assay(A) and scratch assay demonstrate effects of IOX2 on HUVEC migration(B) 
A HUVEC migration assay and scratch assay was performed since it may be a more 
robust overall indicator of angiogenic potency compared to the assessment of VEGF 
secretion using ELISA. Spheroids treated with IOX2 MP had a significant improvement 
on HUVEC migration(Figure 16A), but soluble treatment did not. A scratch assay 
revealed improved HUVEC migration within a scratch when exposed to conditioned 
media of both 60µM IOX2 treated spheroids and PLGA MP treated spheroids(Figure 
16B).  
4.3 Discussion and Conclusions 
Encapsulation of both DMOG and IOX2 into PLGA microparticles proved to be 
difficult due to the amphiphillic nature of DMOG and the low solubility of IOX2. First 
generation IOX2 microparticles successfully increased VEGF secretion of MSC 
spheroids to levels comparable to soluble treatment. However, the irregular morphology 
and presence of IOX2 crystals necessitated adjustment of parameters for microparticle 
formulation.  Multiple iterations of microparticles were necessary for successful IOX2 
encapsulation, while maintaining normal microparticle morphology. The final parameters 
yielded microparticles with 76nmoles IOX2/ mg MPs, which was approximately 9-fold 
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less encapsulation than the first generation microparticles. Second generation 
microparticles did not have an effect on VEGF secretion of MSC spheroids, however, 
IOX2 MP treated spheroids did have an effect on HUVEC migration in a transwell 
HUVEC migration assay suggesting the IOX2 MPs may have had a response on other 
angiogenic factors besides VEGF. 
 While DMOG may be a satisfactory small molecule PHDi to induce a hypoxic 
response, its amphiphillic nature makes drug delivery a challenge. The hydrophobicity of 
IOX2 however, is more amenable to encapsulation. Importantly, IOX2 is a more potent 
and specific PHD inhibitor than DMOG[10], thus it is concluded that IOX2 is the more 
promising PHD inhibitor for drug delivery applications. IOX2 could be encapsulated in 
PLGA microparticles using both DMSO and DMF as the co-solvent for encapsulation of 
the drug. However, due to the lower solubility of IOX2 in DMSO, a large amount of 
IOX2 crystals formed during the emulsion. In the first generation MP spheroid study 
IOX2 crystals were incorporated into the aggregate as evidenced by the phase images of 
the wells in which the crystal structures could be seen. It is likely that once the cells were 
returned to the incubator, the IOX2 was able to dissolve due to the higher temperature 
since this was observed empirically with the soluble stock solution in DMSO. Due to this 
confounding factor, it is impossible to know whether the effects on the VEGF secretion 
of the MSC spheroids were due to actual release from the microparticles or the IOX2 
crystal gradually dissolving. Exposure of the MSCs to high local concentrations of IOX2 
would likely have toxic effects as evidenced from monolayer studies in chapter 3. The 
observation that there were less cells in the IOX2 MP treated spheroids at day 4 of culture 
may support the hypothesis that high local levels of IOX2 are present within the MSC 
spheroids. Since the dissolution of IOX2 crystals is unable to be controlled, it was evident 
that improvements in the microparticle synthesis were necessary. Using DMF as a co-
solvent at a lowed co-solvent percentage (12% rather than 40%) led to microparticles of 
an acceptable size with a more narrow size distribution compared to the first generation 
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MPs and eliminated crystal formation.  The release of IOX2 from the particles over the 
course of one week, mostly occurred in the first 4 days and resulted in the release of 
approximately 20% of total PHDi. However, degradation of PLGA microparticles is 
thought to occur at a faster rate in biological systems than in vitro assays due to the 
presence of cells and enzymes that may expedite degradation[64].  
 The incorporation of second generation PLGA MPs and IOX2 MPs did not 
negatively affect MSC formation nor cell incorporation into spheroids. The incorporation 
efficiency of PLGA MPs was 2-fold higher than IOX-2 MPs. The reasons for this are 
unclear, but may be due to a difference in degradation of the microparticles. Further 
studies are necessary to determine the cause of the lower incorporation efficiency. One 
potential method for improving microparticle incorporation would be to treat the 
microparticles with an adhesive protein such as gelatin which may promote improved 
incorporation into the MSC spheroids. This has previously been done within mouse 
embryonic stem cell aggregates, although it was unlear how much of an improvement in 
incorporation was achieved[65].  
In this study, it was observed that delivery of IOX2 via second generation 
microparticles within MSC spheroids had no effect on the VEGF secretion of MSCs at 
day 4 of culture. This was not surprising since the amount of IOX2 delivered was 250 
times less than an effective soluble dose of 25µM IOX2. This was calculated using the 
known microparticle incorporation per plate, number of MPs/ mass conversion 
(approximately 12.3 million MPs/mg) and the encapsulation efficiency determined 
previously. The estimated amount delivered in the first generation microparticles was 50 
times greater than the second generation (assuming similar incorporation efficiency and 
using 3.5 million MPs/mg conversion within the calculation). This effective first 
generation MP dose was 5 times less than an effective soluble dose suggesting that 
localized delivery may be more potent than soluble delivery. Additionally, it is 
encouraging to observe the presence of PLGA MPs alone did not cause a negative effect 
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on cell number or VEGF secretion of MSC spheroids suggesting that if drug loading 
challenges can be solved, a microparticle method for delivery may still be a viable option 
for enhancing the pro-angiogenic factor secretion of MSC spheroids. 
IOX2 MP treated spheroids were able to successfully promote the migration of 
HUVECs, a common functional in vitro assay demonstrating effects on their ability to 
enhance angiogenesis. The effect on HUVEC migration but not VEGF may indicate that 
IOX2 MPs are causing an increase in secretion of an alternative pro-angiogenic factor 
that was not assessed in this study.  The effect on HUVEC migration was not observed in 
soluble IOX2 treated groups. The reason for this is unclear but may be an effect due to 
the presence of the particles. 
Overall, the major barrier to successful delivery of PHDi to MSC spheroids is 
synthesis of a microparticle that can efficiently encapsulate either DMOG or IOX2 and 
be successfully incorporated into spheroid. This particle must be able to degrade to 
release most of its contents within 7 to 14 days and be non-toxic to the MSCs. Further 
optimization of IOX2 encapsulation using the current oil-in water emulsion technique 
may be worthwhile, however, the investigation of more advanced microparticle synthesis 
such as layer by layer technology [66]may be necessary to obtain desired effects. 
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Chapter 5: Future Work and Considerations 
 Treatment of chronic non-healing wounds with MSCs is currently being 
investigated in pre-clinical trials with promising results. However, engraftment of MSCs 
is very low, and it is likely that the beneficial wound healing effects are through paracrine 
factor secretion. Thus, methods to enhance paracrine factor secretion during the time 
frame that MSCs persist (< 1 week) would be beneficial. The results here demonstrate 
that PHDi enhance MSC pro-angiogenic factor secretion and verifies that IOX2 and 
DMOG are both effective PHDi treatments for MSCs. Additionally, these results are in 
agreement with previous literature that culture of MSCs as spheroids further enhances 
paracrine factor secretion, however technical challenges remain in adequately delivering 
PHDi to spheroid cultures in order to achieve the combinatorial effects of PHDi 
treatments with 3D culture.  
 Future work should investigate pro-angiogenic factor secretion at earlier 
timepoints after PHDi removal. In this study, it appears that the effect of PHDi on VEGF 
secretion is diminished once PHDi is removed from the system. While other studies have 
found that pre-conditioning of MSCs in a soluble treatment of PHDi can have lasting 
effects on engraftment and cell migration up to 18 hours days after treatment [4], no 
thorough studies on lasting effects on paracrine factor secretion have been performed.  
 The angiogenic properties of MSCs is just one mechanism of action intended for 
the use of MSCs in wound healing. MSCs immunomodulatory properties are thought to 
be critical for improving chronic non healing wounds. Thus the effects of IOX2 and 
DMOG on the immunomodulatory effects of MSCs should be investigated.  Hypoxia has 
been shown to either promote or maintain the immunomodulatory properties of 
MSCs[67][68]. The results of the 80 cytokine array support these findings demonstrating 
an increase in relevant immunomodulatory cytokines. This finding is encouraging for 
 44 
potential future investigations of the effects of DMOG or IOX2 on immunomodulatory 
properties of MSCs.  
While delivery of PHDi via microparticles within the spheroids appears 
promising, the ability to deliver an effective dose in the time frame desired was not 
achieved. Future work, will investigate methods for improved delivery of IOX2 via 
microparticles to allow for delivery of an effective dose. One potential approach to this 
would be the synthesis of Layer by Layer(LbL) nanoparticles. The LbL is a very 
adaptable technique and is well suited for small molecules that have low aqueous 
solubilities[66]. This technique has previously been used to deliver doxorubicin via gold 
nanoparticles by conjugating doxorubicin to a polymer using a proteoytically degradeable 
linker[69]. This technique could be promising for IOX2 as they have similar functional 
groups. DMOG would not be promising for this technique as its structure would not 
facilitate conjugation.  
Alternative PLGA-PEG based materials should also be investigated to improve 
the efficiency of encapsulation of IOX2. Co-polymers of PLGA-PEG can be formed into 
both nano/microparticles or polymeric micelles with a hydrophobic core for the aqueous 
IOX2 solution[70]. The formation of nanoparticles using a water-oil-water emulsion of 
PLGA-PEG has previously been shown to encapsulate both hydrophilic and hydrophobic 
drugs[71] which may make this technique a viable option for encapsulation of DMOG 
within PLGA-PEG nanoparticles. Mallarde et al compared PLGA-PEG microspheres 
with PLGA microspheres and found a faster drug release of the compound Teverelix[72] 
which is also beneficial for this system as release on a shorter timeframe of 7 days is 
preferred for wound healing. The synthesis of PLGA-PEG micelles should also be 
investigated for encapsulation of IOX2, however, typically loading efficiency with 
micelles is less than with particles formation.   
To further build upon this research and previous research in the field, an advanced 
method for microparticle synthesis that allows for dual drug delivery and release may 
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prove to be the most effective treatment for wound healing. Dual drug delivery would 
allow for enhancement of the appropriate properties of MSCs at different phases of 
wound healing. For example, in the first three days of wound healing a molecule that 
enhances the immunomodulatory properties of MSCs such as IFN-γ	   could be released 
from microparticles to enhance their immunomodulatory response[73] and preventing a 
chronic inflammatory environment from forming. During the next phase of wound 
healing, when angiogenesis and recruitment of fibroblasts and endothelial cells is 
necessary, IOX2 could be released to enhance MSC paracrine secretion of VEGF. This 
could be achieved using the Layer by Layer technique discussed previously[66]. 
 In conclusion, soluble treatment with both DMOG and IOX2 are successful for 
the enhancement of angiogenic paracrine factor secretion of MSCs in both monolayer and 
spheroid culture formats. However, delivery of these molecules to MSC spheroids using 
microparticles has proven to be challenging. DMOG was determined to be unfavorable 
for the encapsulation technique used here, and would likely be unfavorable for more 
advanced techniques that would require more functional groups for successful 
conjugation to polymers. The encapsulation of IOX2 into MPs was more successful than 





A.1. Appendix  
A.1.1. Semi-Quantitative Antibody Array Layout 
	  
A	   B	   C	   D	   E	  
1	   PC	   PC	   PC	   PC	   NC	  
2	   I-­‐309	   IL-­‐1α	   IL-­‐1β	   IL-­‐2	   IL-­‐3	  
3	  
IL-­‐12	  
(p40/p70)	   IL-­‐13	   IL-­‐15	   IFN-­‐γ	   MCP-­‐1	  
4	   MIP-­‐1δ	   RANTES	   SCF	   SDF-­‐1	   TARC	  
5	  
Oncostatin	  
M	   Thrombopoietin	   VEGF	  
PDGF-­‐
BB	   Leptin	  
6	   FGF-­‐4	   FGF-­‐6	   FGF-­‐7	   FGF-­‐9	  
Fit-­‐3	  
Ligand	  
7	   IGFBP-­‐3	   IGFBP-­‐4	   IL-­‐16	   IP-­‐10	   LIF	  
8	   NT-­‐4	   Osteopontin	  	   Osteopotegerin	   PARC	   PIGF	  
 
	  
F	   G	   H	   I	   J	   K	  
1	   Neg	   ENA-­‐78	   GCSF	   GM-­‐CSF	   RGO	   RGO-­‐α	  
2	   IL-­‐4	   IL-­‐5	   IL-­‐6	   IL-­‐7	   IL-­‐8	   IL-­‐10	  
3	   MCP-­‐2	   MCP-­‐3	   MCSF	   MDC	   MIG	   MIP-­‐1b	  
4	   TGF-­‐β1	   TNF-­‐α	   TNF-­‐β	   EGF	   IGF-­‐1	   Angiogenin	  
5	   BDNF	   BLC	   CK	  β	  8-­‐1	   Eotaxin	   Eotaxin-­‐2	   Eotaxin-­‐3	  
6	   Fractalkine	   GCP-­‐2	   GDNF	   HGF	   IGFBP-­‐1	   IGFBP-­‐2	  
7	   LIGHT	   MCP-­‐4	   MIF	   MIP-­‐3α	   NAP-­‐2	   NT-­‐3	  
8	   TGF-­‐β2	   TGF-­‐β3	   TIMP-­‐1	   TIMP-­‐2	   PC	   PC	  
 





IOX2	   Spheroid,	  V	   Spheroid,	  IOX-­‐2	  
ENA-­‐78	   10.9	   12.4	   8.9	   14.8	  
GCSF	   10.4	   14.0	   8.7	   13.5	  
GM-­‐CSF	   10.1	   14.5	   8.4	   12.7	  
GRO	   17.9	   22.9	   44.1	   24.0	  
GRO-­‐α	   9.9	   15.4	   9.0	   13.4	  
I-­‐309	   12.7	   15.1	   8.8	   14.5	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IL-­‐1α	   12.7	   16.3	   9.4	   15.3	  
IL-­‐1β	   13.2	   15.9	   10.6	   14.2	  
IL-­‐2	   11.7	   12.9	   9.6	   12.8	  
IL-­‐3	   13.1	   16.6	   12.5	   17.4	  
IL-­‐4	   10.0	   11.6	   8.1	   12.5	  
IL-­‐5	   11.3	   12.8	   8.5	   13.4	  
IL-­‐6	   163.8	   192.5	   160.9	   132.3	  
IL-­‐7	   13.3	   16.3	   12.4	   13.4	  
IL-­‐8	   57.9	   47.0	   139.6	   99.9	  
IL-­‐10	   14.1	   30.4	   15.8	   32.6	  
IL-­‐12	  (p40/p70)	   15.4	   19.1	   13.6	   20.8	  
IL-­‐13	   11.0	   12.9	   8.2	   13.4	  
IL-­‐15	   11.8	   16.3	   8.9	   14.9	  
IFN-­‐γ	   12.4	   14.3	   10.5	   13.1	  
MCP-­‐1	   101.3	   57.9	   106.4	   71.6	  
MCP-­‐2	   12.6	   13.5	   10.2	   13.7	  
MCP-­‐3	   11.7	   13.0	   9.1	   12.6	  
MCSF	   14.6	   16.7	   10.6	   14.1	  
MDC	   12.8	   16.8	   10.1	   13.8	  
MIG	   11.9	   13.0	   10.0	   12.2	  
MIP-­‐1b	   30.5	   34.1	   32.3	   34.1	  
MIP-­‐1δ	   11.6	   12.8	   9.4	   13.7	  
RANTES	   28.9	   29.4	   25.4	   36.5	  
SCF	   12.7	   15.4	   9.5	   15.4	  
SDF-­‐1	   13.4	   15.4	   10.7	   14.6	  
TARC	   13.6	   32.1	   11.4	   28.7	  
TGF-­‐β1	   11.5	   18.4	   9.0	   19.1	  
TNF-­‐α	   14.4	   20.7	   11.0	   20.1	  
TNF-­‐β	   13.4	   20.9	   10.2	   18.8	  
EGF	   14.9	   17.4	   11.6	   16.0	  
IGF-­‐1	   13.8	   14.7	   11.4	   13.9	  
Angiogenin	   11.4	   13.5	   9.5	   12.4	  
Oncostatin	  M	   28.6	   32.2	   24.2	   33.5	  
Thrombopoietin	   11.9	   13.2	   9.3	   13.2	  
VEGF	   14.7	   35.5	   12.2	   32.0	  
PDGF-­‐BB	   11.1	   18.6	   9.0	   17.1	  
Leptin	   11.7	   20.7	   9.5	   19.7	  
BDNF	   33.0	   31.2	   12.5	   23.0	  
BLC	   13.0	   15.3	   9.6	   14.7	  
CK	  β	  8-­‐1	   18.9	   19.5	   14.7	   18.4	  
Eotaxin	   14.8	   28.9	   11.0	   24.4	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Eotaxin-­‐2	   19.3	   28.1	   16.9	   25.6	  
Eotaxin-­‐3	   27.0	   29.0	   28.2	   32.4	  
FGF-­‐4	   11.3	   12.8	   9.7	   12.7	  
FGF-­‐6	   11.6	   16.0	   9.3	   15.8	  
FGF-­‐7	   11.5	   14.4	   9.4	   12.7	  
FGF-­‐9	   14.2	   19.3	   12.7	   16.8	  
Fit-­‐3	  Ligand	   11.2	   13.0	   9.4	   12.5	  
Fractalkine	   13.6	   14.4	   11.0	   13.4	  
GCP-­‐2	   14.7	   14.9	   11.7	   14.3	  
GDNF	   24.6	   25.5	   18.8	   25.6	  
HGF	   15.2	   16.7	   11.7	   14.6	  
IGFBP-­‐1	   17.4	   21.0	   14.3	   19.3	  
IGFBP-­‐2	   18.1	   38.4	   17.5	   38.8	  
IGFBP-­‐3	   14.6	   31.4	   11.9	   26.7	  
IGFBP-­‐4	   12.1	   15.6	   9.9	   14.0	  
IL-­‐16	   16.1	   19.9	   14.8	   16.1	  
IP-­‐10	   16.2	   30.6	   16.1	   26.5	  
LIF	   24.1	   45.3	   27.6	   44.6	  
LIGHT	   14.0	   15.6	   12.3	   14.2	  
MCP-­‐4	   11.9	   12.9	   9.1	   11.9	  
MIF	   21.4	   26.1	   18.7	   28.1	  
MIP-­‐3α	   13.5	   14.2	   9.6	   12.4	  
NAP-­‐2	   28.0	   30.8	   23.7	   27.7	  
NT-­‐3	   15.5	   45.6	   13.9	   39.0	  
NT-­‐4	   10.7	   13.7	   10.0	   12.2	  
Osteopontin	   15.5	   27.2	   12.9	   17.2	  
Osteopotegerin	   150.7	   160.6	   27.6	   23.0	  
PARC	   17.0	   22.4	   13.8	   16.4	  
PIGF	   14.2	   17.6	   14.6	   15.0	  
TGF-­‐β2	   34.6	   55.5	   33.4	   49.3	  
TGF-­‐β3	   13.9	   13.5	   11.0	   13.6	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